ImmunoGen Announces $200 Million Non-Dilutive Royalty Transaction
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced a $200 million non-dilutive royalty transaction with funds managed by TPG Special Situations Partners (“TSSP”).
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.